HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 10-29-2013, 11:13 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Unicorn search: MM-302 is a HER2-targeted nanotherapeutic

MM-302

MM-302 is a HER2-targeted nanotherapeutic consisting of the chemotherapeutic doxorubicin, encapsulated in a liposomal sphere. Doxorubicin has been a standard therapy for the treatment of breast cancer for more than 30 years. Despite the demonstrated efficacy of this therapy, its use is limited due to an increased incidence of cardiotoxicity in individuals repeatedly exposed to the free form of the drug. By the encapsulation of doxorubicin inside of a liposome, MM-302 is designed to minimize exposure of healthy tissues such as the heart, while exposure is simultaneously maximized to cancerous tissues. In preclinical models, once MM-302 is deposited in the tumor microenvironment,proprietary HER2 targeting technology utilizes HER2-targeting antibodies on the surface of the liposome bind to HER2-expressing cancer cells, promoting the internalization of the entire liposome. Once inside the cancer cell, the liposome breaks down and releases doxorubicin intracellularly, promoting cell death.
Unlike other HER2-targeted agents, MM-302 is not designed to inhibit HER2 signaling pathways and relies on HER2 as a means to identify and gain access to the cancer cells. The potential benefit of this approach is to leave this critical pathway, which is essential for healthy cells, still functional, thereby limiting damage and reducing side effects to non-cancerous cells.
Our research suggests that there is a tremendous opportunity for MM-302 to:

  • Minimize drug exposure to healthy tissues such as the heart
  • Increase tumor delivery of a proven chemotherapy
  • Selectively deliver doxorubicin to HER2 overexpressing cancer cells
MM-302 in the Clinic

Currently, MM-302 is being tested in a Phase 1 clinical study for patients with HER2+ breast cancer. Based on our research, future clinical studies will explore MM-302’s potential in other types of HER2+ cancers, tumors with leaky vasculatures and in combination with other targeted agents.
CLICK HERE to learn more about MM-302 in the Clinic
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 03:10 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter